1 APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004

2. Falkai P, Wobrock T, Lieberman J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132-91

5 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.

6. Lieberman JA, Koreen AR, Chakos M et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57 Suppl 9:5-9.

7. Breier A, Buchanan RW, Kirkpatrick B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994 Jan;151(1):20-6.

8. Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9.

9 National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.

10. Howard R, Rabins PV, Seeman MV et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000 Feb;157(2):172-8

11. Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16(2):293-307

12. Murray RM, Fearon P. The developmental 'risk factor' model of schizophrenia. J Psychiatr Res. 1999 Nov-Dec;33(6):497-9

13. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N et al. Molecular mechanisms of schizophrenia. Cell Physiol Biochem. 2007;20(6):687-702.

22. Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7.

23. Weiden PJ, Kozma C, Grogg A et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004 Aug;55(8):886-91

24. Koen L, Uys S, Niehaus DJ et al. Negative symptoms and HIV/AIDS risk-behavior knowledge in schizophrenia. Psychosomatics. 2007 Mar-Apr;48(2):128-34